Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q2 2025
Top Holdings30 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 5M | $859.5M | 15.1% | $127.90 | +34.66% | 17 qtrssince 2021-Q2 | Decreased 0 |
UNITED THERAPEUTICS CORP | 2.4M | $681M | 11.9% | $151.50 | +87.63% | 19 qtrssince 2020-Q4 | Decreased 0 |
ARGENX SE - ADR | 1.2M | $647.7M | 11.3% | $224.78 | +149.20% | 26 qtrssince 2019-Q1 | Decreased 0 |
MADRIGAL PHARMACEUTICALS INC | 1.9M | $567.5M | 9.9% | $157.20 | +91.32% | 26 qtrssince 2019-Q1 | Decreased 0 |
Krystal Biotech, Inc. | 2.7M | $365.6M | 6.4% | $95.79 | +44.98% | 15 qtrssince 2021-Q4 | Decreased 0 |
KYMERA THERAPEUTICS INC | 6.6M | $286.1M | 5.0% | $32.85 | +34.32% | 16 qtrssince 2021-Q3 | Increased 62 |
APELLIS PHARMACEUTICALS INC | 12.2M | $211.6M | 3.7% | $42.79 | -59.27% | 18 qtrssince 2021-Q1 | Unchanged 0 |
| 7.1M | $200.2M | 3.5% | $26.98 | +7.62% | 21 qtrssince 2020-Q2 | Decreased 0 | |
MoonLake Immunotherapeutics Class A | 4.2M | $195.9M | 3.4% | $51.26 | -7.30% | 9 qtrssince 2023-Q2 | Increased 79 |
AKERO THERAPEUTICS INC | 3.5M | $186.8M | 3.3% | $56.19 | 0.00% | 1 qtr | New 85 |
SOLENO THERAPEUTICS INC | 2.1M | $171.7M | 3.0% | $42.20 | +97.26% | 7 qtrssince 2023-Q4 | Decreased 0 |
XENON PHARMACEUTICALS INC | 5.4M | $169M | 3.0% | $21.38 | +51.51% | 26 qtrssince 2019-Q1 | Decreased 0 |
ARROWHEAD PHARMACEUTICALS IN | 10.6M | $167.5M | 2.9% | $26.83 | -40.06% | 9 qtrssince 2023-Q2 | Decreased 0 |
MERUS N V | 3.2M | $166M | 2.9% | $41.14 | +28.81% | 8 qtrssince 2023-Q3 | Increased 56 |
VERA THERAPEUTICS INC | 6.3M | $148.4M | 2.6% | $40.72 | -44.37% | 6 qtrssince 2024-Q1 | Increased 58 |
AMICUS THERAPEUTICS INC | 18M | $103.1M | 1.8% | $11.07 | -46.43% | 26 qtrssince 2019-Q1 | Decreased 0 |
ALKERMES PLC | 2.9M | $83M | 1.5% | $28.74 | -0.44% | 3 qtrssince 2024-Q4 | Increased 56 |
OCULAR THERAPEUTIX INC | 7.4M | $68.7M | 1.2% | $8.84 | +4.25% | 6 qtrssince 2024-Q1 | Decreased 0 |
89BIO INC | 6.8M | $66.3M | 1.2% | — | — | 3 qtrssince 2024-Q4 | Increased 51 |
CENTESSA PHARMACEUTICALS PLC | 5M | $65.7M | 1.2% | $14.31 | -8.26% | 2 qtrssince 2025-Q1 | Increased 58 |
Avoro Capital Advisors LLC manages $5.7B across 30 positions as of Q2 2025. Top holdings: ASND (15.1%), UTHR (11.9%), ARGX (11.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Added 1 new position, exited 4, increased 10, trimmed 17. Top move: AKRO (NEW, conviction 85). Portfolio: $5.7B across 30 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer